Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adlai Nortye Starts Phase III Trial of Pan- PI3K Inhibitor in Head and Neck Carcinoma

publication date: Apr 15, 2021

Adlai Nortye, a Hangzhou-New Jersey biopharma, has dosed the first patient in a global Phase III trial of Buparlisib at the Shanghai Eastern Hospital Medical Center. The trial will test Buparlisib, an oral pan-PI3K inhibitor, as a second-line therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients must have disease that progressed after a previous PD-1/PD-L1 treatment. Adlai Nortye said the trial is the first global multicenter Phase III trial of a PI3K inhibitor as an HNSCC therapy. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital